The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1568
March 25, 2019
View Complete Issue         Table of Contents 2019 
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
March 25, 2019 (Issue: 1568)
Sarecycline (Seysara — Allergan), a new oral tetracycline antibiotic, has been approved by the FDA for once-daily treatment of inflammatory lesions of non-nodular moderate to severe acne in patients ≥9 years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sarecycline (Seysara) - Another Oral Tetracycline for Acne
Article code: 1568b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.